Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia

Wagenvoort, G.H.J.; Sanders, Elisabeth A. M.; Melker, Hester E. de; Ende, Arie van der; Vlaminckx, Bart J. M.; Knol, Mirjam J.

doi:10.1016/j.vaccine.2017.02.037

Cited by 23 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mortality rate was 17%, similar to the results obtained by others in larger series [5,11,13] and most deaths (55%) occurred within the first 3 days after hospital admission as already has been described [4,5]. In our study, severity of disease at onset was the most important factor associated with death.…”

Section: Discussionsupporting

confidence: 91%

“…Regarding underlying conditions and in agreement with previous published results, cigarette smoking, was the most prevalent risk factor, followed by chronic obstructive lung disease and congestive heart failure [10,12,13]. In fact, current cigarette smoking was predictive of BPP in one study [8] and was associated to septic shock in another [14].…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Bacteremic Pneumococcal Pneumonia: a Longitudinal Study in 279 Adult Patients from a Single Center

Gentile¹,

Hernández²,

Sparo³

et al. 2018

JRI

View full text Add to dashboard Cite

Despite the fact that BPP is a frequent and severe disease, there is minimal information regarding BPP in our city. We report here the result of 26-year prospective study in patients with BPP treated in our hospital, to assess local disease incidence, clinical, radiographic and microbiological features, as well as to evaluate factors related to mortality. Methods Study Design and Study Population This was a longitudinal, prospective observational study of adult patients with BPP evaluated at the Santamarina Hospital in the city of Tandil. The hospital is a 130-bed primary care community hospital. Tandil is a city with a population of 130,000 inhabitants located in the province of Buenos Aires, Argentina.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 87%

Bacteremic Pneumococcal Pneumonia: a Longitudinal Study in 279 Adult Patients from a Single Center

Gentile¹,

Hernández²,

Sparo³

et al. 2018

JRI

View full text Add to dashboard Cite

show abstract

“…167 Two more recent studies indicated similar findings. 168,169 The former study, in patients with IPD and bacteremic and nonbacteremic pneumococcal pneumonia, documented that in patients with both nonpneumonia IPD and pneumococcal pneumonia who survived 30 days, approximately 40% died within the following 5 years. 168 The study documented that even noninvasive pneumococcal pneumonia (urine antigen test positive) had an impaired long-term outcome and that the increased long-term mortality was mainly associated with comorbid disease.…”

Section: Impact Of Vaccination With Pcv On Pneumococcal Antibiotic Rementioning

confidence: 99%

“…168,169 The former study, in patients with IPD and bacteremic and nonbacteremic pneumococcal pneumonia, documented that in patients with both nonpneumonia IPD and pneumococcal pneumonia who survived 30 days, approximately 40% died within the following 5 years. 168 The study documented that even noninvasive pneumococcal pneumonia (urine antigen test positive) had an impaired long-term outcome and that the increased long-term mortality was mainly associated with comorbid disease. The latter study documented that adult patients who had survived an episode of invasive pneumococcal pneumonia died before their life expectancy, with only 9% of the patients living longer than their life expectancy.…”

Section: Impact Of Vaccination With Pcv On Pneumococcal Antibiotic Rementioning

confidence: 99%

The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia

Feldman

Anderson

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

AbstractWith the notable exceptions of the United States and Canada in particular, the global burden of disease in adults due to invasive infection with the dangerous respiratory, bacterial pathogen, Streptococcus pneumoniae (pneumococcus) remains. This situation prevails despite the major successes of inclusion of polysaccharide conjugate vaccines (PCVs) in many national childhood immunization programs and associated herd protection in adults, as well as the availability of effective antimicrobial agents. Accurate assessment of the geographic variations in the prevalence of invasive pneumococcal disease (IPD) has, however, been somewhat impeded by the limitations imposed on the acquisition of reliable epidemiological data due to reliance on often insensitive, laboratory-based, pathogen identification procedures. This, in turn, may result in underestimation of the true burden of IPD and represents a primary focus of this review. Other priority topics include the role of PCVs in the changing epidemiology of IPD in adults worldwide, smoking as a risk factor not only in respect of increasing susceptibility for development of IPD, but also in promoting pneumococcal antibiotic resistance. The theme of pneumococcal antibiotic resistance has been expanded to include mechanisms of resistance to commonly used classes of antibiotics, specifically β-lactams, macrolides and fluoroquinolones, and, perhaps somewhat contentiously, the impact of resistance on treatment outcome. Finally, but no less importantly, the role of persistent antigenemia as a driver of a chronic, subclinical, systemic proinflammatory/procoagulant phenotype that may underpin the long-term sequelae and premature mortality of those adults who have recovered from an episode of IPD, is considered.

show abstract

“… 89 – 91 In our own studies, the (all-cause) long-term mortality of CAP patients is equally high: after 1 year, 17% of these patients have died, and after 5 years, it was 27%. 92 , 93 …”

Section: Outcome Of Pneumoniamentioning

confidence: 99%

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Rijkers

Yousif

Spoorenberg

et al. 2018

RMHP

View full text Add to dashboard Cite

Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.

show abstract

Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia

Cited by 23 publications

References 36 publications

Bacteremic Pneumococcal Pneumonia: a Longitudinal Study in 279 Adult Patients from a Single Center

Bacteremic Pneumococcal Pneumonia: a Longitudinal Study in 279 Adult Patients from a Single Center

The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia

Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly

Contact Info

Product

Resources

About